Profile: Apredica specializes in providing preclinical contract testing services for the evaluation and optimization of the ADME, toxicity & pharmacokinetic properties of drug candidates early in the drug-discovery process. The preclinical testing stage of drug development focuses on obtaining critical safety and pharmacology data needed to take a drug to clinical testing in humans. Preclinical testing provides the opportunity for improving the efficiency of bringing new drugs to market. We offer discovery-focused ADME Tox services focused on the pre-GLP phase of drug development. We offer a comprehensive array of toxicity assays. We provide fast turnaround for a wide variety of toxicology research for drug-discovery programs, including both in vitro and in vivo toxicology research. We provide a suite of predictive in vitro toxicology services to get the toxicity data needed quickly, accurately, and efficiently. These are available in screening, primary profiling, and full profiling modes. We offer in vitro cytotoxicity testing of test articles in HepG2, NIH3T3, or HaCaT cells by neutral red or MTT assays, as well as high-content imaging. We also provide various specialized toxicity tests, and routinely develop customized tests for clients' specialized needs. Bioanalytical testing provides quantitative measurement of an active drug and/or its metabolites in biological matrices. Custom specific and sensitive bioanalytical methods are required to make these measurements. Our bioanalytial lab employs high-throughput LC/MS/MS and HPLC equipment to offer the most sensitive bioanalytical method possible. Our bioanalytical lab offers bioanalytical services separately or in conjunction with our other CRO services including pharmacokinetic studies, pharmacodynamic studies, toxicokinetic studies, pre-formulation, chemical stability, metabolic stability and in vitro ADME studies.